Vicplas International Ltd risk profile
62 Stretched several inputs deteriorating together
Measured 21 October 2026 from 569.SI's filed statements. Recomputed nightly.
62 (Stretched), driven by Cash conversion at 96, over 4 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 64 | Stretched | Stable | Drawdown from the 52-week high — 34.0% |
| Operating pressure | 54 | Elevated | Worsening | Costs outgrowing revenue — +6.4 percentage points |
| Cash conversion | 96 | Acute | Worsening | Capital spending against operating cash — 2.16x |
| Leverage and coverage | 46 | Elevated | Worsening | Net debt to EBITDA — 3.97x |
| Competitive position | Reads research_and_development, operating_income, revenue, peer cohort and disclosed transition KPIs. No reading is stored for this company. | |||
| Concentration | Reads identified supplier spend, customers above the 10% disclosure threshold and revenue by region. No reading is stored for this company. | |||
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.
Healthcare companies with a risk reading
Lilly(Eli) & Company 33Johnson & Johnson 39Abbvie Inc 57Unitedhealth Group Inc 43Roche Holding AG 35Merck & Co Inc 35Novartis AG 29Novartis AG 31Astrazeneca plc 33Thermo Fisher Scientific Inc 44AMGEN Inc 47Gilead Sciences Inc 51
Financials, valuation and price history for Vicplas International Ltd